| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Alkaline phosphatase does not have a traditional drug target but is an enzyme that acts on various phosphate-containing substrates. It hydrolyzes phosphate esters, releasing inorganic phosphate. It is involved in phosphate metabolism and is used as a marker for various conditions. It is commonly used in molecular biology for dephosphorylation of DNA and RNA, and for conjugation to antibodies for detection in ELISA, Western blotting, and histochemical detection.
|
|---|---|
| ln Vitro |
In vitro, alkaline phosphatase is widely used as a tool in molecular biology. It is used for the dephosphorylation of DNA and RNA vectors to prevent self-ligation. It is also used for conjugation to antibodies and other proteins for ELISA, Western blotting, and histochemical detection. One unit of the enzyme hydrolyzes 1 µmole of p-nitrophenol phosphate per minute at 25°C, pH 8.0.
|
| ln Vivo |
In vivo, alkaline phosphatase plays a role in phosphate metabolism. It is found in various tissues, including bone, liver, intestine, and placenta. Elevated levels of alkaline phosphatase in the blood can indicate liver disease or bone disorders. The enzyme is not used as a therapeutic agent but is an important diagnostic marker.
|
| Enzyme Assay |
In vitro enzyme assays for alkaline phosphatase typically involve measuring the hydrolysis of a chromogenic substrate, such as p-nitrophenyl phosphate (pNPP), to p-nitrophenol, which can be detected by absorbance at 405 nm. One unit is defined as the amount of enzyme that hydrolyzes 1 µmole of p-nitrophenol phosphate per minute at 25°C, pH 8.0. The enzyme's activity can be inhibited by various compounds, including phosphate analogs.
|
| Cell Assay |
Alkaline phosphatase is not typically used in cell-based assays as a bioactive compound. However, it may be used as a detection reagent in cell-based assays, such as ELISA, where it is conjugated to antibodies for the detection of specific antigens. It may also be used in histochemical staining to detect alkaline phosphatase activity in cells or tissues.
|
| Animal Protocol |
In vivo animal studies using alkaline phosphatase are not typically performed as a therapeutic intervention. However, the enzyme is used as a diagnostic marker in animal models of disease. For example, elevated alkaline phosphatase levels may be measured in animal models of liver disease or bone disorders to assess disease progression.
|
| ADME/Pharmacokinetics |
Alkaline phosphatase has a CAS number of 9001-78-9. It is an enzyme with a molecular weight that varies depending on the source (e.g., ~140 kDa for the intestinal form). It is a zinc protein. The enzyme is typically supplied as a lyophilized powder or solution and should be stored according to the manufacturer's recommendations. It is stable under alkaline conditions.
|
| Toxicity/Toxicokinetics |
The toxicity profile of alkaline phosphatase is not a concern, as it is an enzyme that is naturally present in the body. When used in research, it is generally considered safe. However, it is intended for research use only and is not approved for therapeutic use in humans. Standard laboratory safety practices should be followed.
|
| References | |
| Additional Infomation |
Alkaline phosphatase (AP) is an oral medication with very few side effects. AP acts only locally in the colon, reducing persistent colonic inflammation caused by Gram-negative bacterial endotoxins and extracellular ATP in patients with ulcerative colitis (UC). AP is an enzyme that catalyzes the conversion of orthophosphate monoesters and water into alcohols and orthophosphates. EC 3.1.3.1. Indications: It has been studied for the treatment of ulcerative colitis. Mechanism of Action: Gram-negative bacterial endotoxins (LPS) and adenosine triphosphate (ATP) are two substrates that can disrupt organ homeostasis. Studies have shown that the dephosphorylation of LPS and extracellular ATP by AP can reduce inflammation-induced damage, thereby restoring homeostasis in target organs such as the gastrointestinal tract and kidneys. In the gastrointestinal tract, the main source of LPS is colonized Gram-negative microorganisms. The colonic mucosal surface of patients with ulcerative colitis (UC) is characterized by intermittent damage and increased permeability due to chronic inflammation. The consequences of intestinal mucosal damage include decreased alkaline phosphatase (AP) levels and increased infiltration of LPS-reactive cells, thereby maintaining the inflammatory response. In the gastrointestinal tract, the primary source of LPS is colonized Gram-negative microorganisms. AP alleviates LPS-mediated inflammation by inhibiting intestinal epithelial cell activation and preventing systemic inflammatory responses caused by endotoxin leakage through the inflamed intestinal mucosa with increased permeability.
Alkaline phosphatase (APase) (CAS 9001-78-9) is a hydrolase enzyme that catalyzes the removal of phosphate groups from various molecules under alkaline conditions. It is widely used in molecular biology for dephosphorylation of DNA and RNA, and for conjugation to antibodies for detection in ELISA, Western blotting, and histochemical detection. It has wide specificity and also catalyzes transphosphorylations. |
| Exact Mass |
496.275
|
|---|---|
| CAS # |
9001-78-9
|
| PubChem CID |
18985873
|
| Appearance |
White to off-white solid powder
|
| Density |
1.12 g/mL at 20 °C
|
| Boiling Point |
1.41 °C
|
| LogP |
-5
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
35
|
| Complexity |
846
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1CCCN1C(C(C)N)=O)NCC(N1CCCC1C(NC(C(=O)O)CCC/N=C(\N)/N)=O)=O
|
| InChi Key |
ITZMJCSORYKOSI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H36N8O6/c1-12(22)19(33)29-10-4-6-14(29)17(31)26-11-16(30)28-9-3-7-15(28)18(32)27-13(20(34)35)5-2-8-25-21(23)24/h12-15H,2-11,22H2,1H3,(H,26,31)(H,27,32)(H,34,35)(H4,23,24,25)
|
| Chemical Name |
2-[[1-[2-[[1-(2-aminopropanoyl)pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT00430859
Conditions:Sepsis|Multiple Organ Dysfunction SyndromeLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000769-13
Condition:Severe sepsis and septic shockProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA